Trial site
Hospital Vithas Parque San Antonio
Malaga, 29016, SpainNot linked to an institution yet
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 21 trial
- Status
- Active, not recruiting6 trials
- Recruiting3 trials
- Not yet recruiting1 trial
- Lead sponsor
- Merz Therapeutics GmbH2 trials
- Amgen Inc.1 trial
- Bristol-Myers Squibb1 trial
- DualityBio Inc.1 trial
- Novartis Pharmaceuticals1 trial
- and 4 more
Running trials
Not yet recruiting
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
NCT07340658· Phase 3· Rovi Pharmaceuticals Laboratories· Source
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569· Phase 2· Sanofi· Source
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
2024-512914-16-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713· Phase 3· Merz Therapeutics GmbH· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700· Phase 3· Merz Therapeutics GmbH· Source
Active, not recruiting
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337· Phase 3· DualityBio Inc.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error